Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

Foresight Diagnostics has launched the PRECISE-HL trial, which will use the Foresight Clarity LDT to treat patients with ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...